Abstracts tagged "risk assessment"

Abstract Number: 0674 • ACR Convergence 2024
Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data
Sara Shahid¹, Tyson Barrett², Sonia Manocha¹ and Tanmayee Bichile¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ)-associated retinal toxicity and vision loss are significant challenges, with a 2% prevalence in patients using HCQ for over 10 years and up…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 2340 • ACR Convergence 2024
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Jessica A Walsh¹, Shaobo Pei², Gopi Penmetsa³, Swetha Alexander⁴, Nga Lori Ly⁵, Rosario Adriana Molano-Romero⁴, April Conlon⁶, Catherine Bakewell⁷, Soumya Reddy⁸, Jose Scher⁹ and Alexis Ogdie¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²University of Utah, Thousand Oaks, CA, ³University Of Utah Hospital, Salt Lake City, UT, ⁴University of Utah Health, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah, Sandy, UT, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸NYU Grossman School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
Abstract Number: 0694 • ACR Convergence 2024
A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Stefano Di Donato¹, Michael Hughes², John Pauling³, Marco Matucci-Cerinic⁴, Lesley-Anne Bissell⁵, Edward Jude⁶, Christopher Denton⁷, Yannick Allanore⁸, Marie-Elise Truchetet⁹ and Francesco Del Galdo¹⁰, and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University San Raffaele Milano, Milano, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸Université Paris Cité, Paris, France, ⁹Bordeaux University Hospital, Bordeaux, France, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 2389 • ACR Convergence 2024
Choroidal Thickness in Active Lupus Nephritis
Leticia Maria Kolachinski R Brandao¹, Lucas Parente de Andrade², Débora Cordeiro do Rosário³, Paula Letícia De Queiroz e Barbosa⁴, Francisco Formiga³, Carolina Torres Ribeiro⁵, Tatiana do Nascimento Pedrosa³, Maria Fernanda Abalem de Sá Carricondo⁶, Pedro Carlos Carricondo², Eloisa Bonfa³ and Michelle Remiao Ugolini Lopes³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Campinas, SP, Brazil, ²Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, ⁵Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Lupus choroidopathy was reported to be a marker of severe systemic lupus erythematosus (SLE) activity, commonly associated with nephropathy. However, it remains controversial if…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 2399 • ACR Convergence 2024
Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization
Simran Bhimani¹, Anand Maligireddy², Shivang Chaudhary³, Yash Deshpande², Kishan Patel⁴, Sameer Bhimani², Shreyas Patel² and Birju Bhatt⁵, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center, GME, Scranton, PA, ³Saint Louis University, St. Louis, MO, ⁴Riverside Community Hospital, Riverside, CA, ⁵Geisinger, Wilkes Barre, PA
Background/Purpose: Ischemic stroke poses significant risks for patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), both conditions associated with heightened cardiovascular complications. Endovascular…
Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Melody Esmaeili¹, Linh Truong², Nicole Ridolfi³, Eugenia Chen⁴ and Maida wong⁵, ¹University of California, Irvine, Orange, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California, Irvine, Newport Beach, CA, ⁴Long Beach VA Hospital, Irvine, CA, ⁵Long Beach VA Hospital, Los Angeles, CA
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
Abstract Number: 0721 • ACR Convergence 2024
Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study
Xavier Puéchal¹, Michele Iudici¹, Elodie Perrodeau², Claire Goulvestre³, Pascal cohen⁴, Alexis Régent¹, Luc Mouthon⁵, Loïc Guillevin⁴, Raphael Porcher⁶ and Benjamin Terrier⁷, ¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²Hôtel-Dieu, Paris, France, ³Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a frequently relapsing disease for which a meta-analysis concluded that an increase or persistence of ANCA during remission is only…
Abstract Number: 1723 • ACR Convergence 2024
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Fabio Cacciapaglia¹, Vincenzo Venerito², Gian Luca Erre³, Matteo Piga⁴, Andreina Manfredi⁵, Garifallia Sakellariou⁶, Ombretta Viapiana⁷, Elisa Gremese⁸, Elena Bartoloni Bocci⁹, Francesca Romana Spinelli¹⁰ and Fabiola Atzeni¹¹, and "Cardiovascular Obesity and Rheumatic DISeases" Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit, DiMePRe-J University of Bari, Bari, Italy, ³Rheumatology Unit - University of Sassari, Sassari, Italy, ⁴Rheumatology Unit - University of Cagliari, Cagliari, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁷Rheumatology Unit, University of Verona, Verona, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹⁰Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹¹University of Messina, Italy, Messina, Italy
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased cardiovascular (CV) risk, but traditional CV risk factors and available 10-year CV risk estimation models may not…
Abstract Number: 2418 • ACR Convergence 2024
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Matthew Linnik¹, Guilherme Rocha², David Gemperline³, Ernst Dow³, Christoph Preuss³, Helen Masson⁴, Olivia Ellis⁴, Ana Accioly³, Maja Hojnik⁵, Kira Rubtsova¹, Robert Benschop⁶, Mark Chambers⁷, Mark Genovese³ and Richard Higgs³, ¹Eli Lilly, San Diego, CA, ²Eli Lilly, Indianapolis, IN, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly and Co, San Diego, CA, ⁵Eli Lilly and Co., Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Zionsville, IN
Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
Abstract Number: 0209 • ACR Convergence 2024
Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
Abstract Number: 0851 • ACR Convergence 2024
Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Lihi Eder¹, Ricardo Acayaba de Toledo², Fahmeen Afgani³, Catherine Bakewell⁴, Philippe Carron⁵, Basant Elnady⁶, Amir Haddad⁷, Arthur Kavanaugh⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, NZEUSSEU TOUKAP Adrien¹², Marcos Rosemffet¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Ágnes Sarolta Szentpétery¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Ilaria Tinazzi¹⁹, Janeth Yinh¹⁰, Gurjit Kaeley²⁰ and Sibel Aydin²¹, ¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ²FAMERP, São José do Rio Preto, Brazil, ³Women's College Hospital, Toronto, Canada, ⁴Intermountain Health Care, Salt Lake City, UT, ⁵UZ Gent, Gent, Belgium, ⁶Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ⁷Carmel Medical Centre, Haifa, Israel, ⁸University of California San Diego, La Jolla, CA, ⁹GRAPPA - Patient Research Partner, Haifa, Israel, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Hospital Italiano de Buenos Aires, buenos aires, Argentina, ¹²Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ¹³Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁴Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, FL, ¹⁶Uppsala University Hospital, Uppsala, Sweden, ¹⁷University of California, San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²⁰UF COM-J, Ponte Vedra Beach, FL, ²¹University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].